BiologicalDrug
SEPHB4-HSA clinical trials
Also written sEphB4-HSA and Recombinant EphB4-HSA Fusion Protein.
- studies test it
- 11
- open now
- 3
- in phase 3
- 1
- first study started
- 2016
Keep track of what changes. Save the SEPHB4-HSA studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 8
University of Southern California (5) · Vasgene Therapeutics, Inc (3) · AIDS Malignancy Consortium (1) · University of Colorado, Denver (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Pembrolizumab (3) · Cetuximab (1) · Azacitidine (1) · Decitabine (1)
Studies
Open first, then newest update. How each study uses SEPHB4-HSA is read from its arms, and is right about nine times in ten.
Testing it · 11
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsRecruitingPhase 2/3Vasgene Therapeutics, IncNCT06493552Written as SEphB4-HSA
- A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaRecruitingPhase 2Vasgene Therapeutics, IncNCT04486781Written as Pembrolizumab + sEphB4-HSA
- A Study of sEphB4-HSA in Kaposi SarcomaRecruitingPhase 2Vasgene Therapeutics, IncNCT03993106Written as sEphB4-HSA
- Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsActive, not recruitingPhase 2University of Southern CaliforniaNCT02717156Written as Recombinant EphB4-HSA Fusion Protein
- Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating AgentTerminatedPhase 2University of Southern CaliforniaNCT03146871Written as Recombinant EphB4-HSA Fusion Protein
- sEphB4-HSA in Treating Patients With Kaposi SarcomaCompletedPhase 2AIDS Malignancy ConsortiumNCT02799485Written as Recombinant EphB4-HSA Fusion Protein
- Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475CompletedPhase 2University of Southern CaliforniaNCT03049618Written as Recombinant EphB4-HSA Fusion Protein
- sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCCCompletedPhase 1University of Colorado, DenverNCT04091867Written as sEphB4-HSA with chemotherapy
- sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder CancerWithdrawnPhase 1University of Southern CaliforniaNCT03552796Written as Recombinant EphB4-HSA Fusion Protein
- sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate CancerStatus unknownPhase 2Northwestern UniversityNCT04033432Written as Recombinant EphB4-HSA Fusion Protein
- sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerTerminatedPhase 1University of Southern CaliforniaNCT02767921Written as Recombinant EphB4-HSA Fusion Protein
Given in every arm · 2 — SEPHB4-HSA is usual care beside what is tested
- Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT02495896Written as Recombinant EphB4-HSA Fusion Protein
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedPhase 1University of Southern CaliforniaNCT03519984Written as Recombinant EphB4-HSA Fusion Protein
Codes
What other systems call SEPHB4-HSA · ClinicalTrials.gg INT017924
- UNII (FDA) SO0RV2V6EJSEPHB4-HSAOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SO0RV2V6EJ | SEPHB4-HSA | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.